Phase 3 Readout

PROK: Phase 3 Topline: A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type

Name: Phase 3 Topline: A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type
Start: 2029-12-01
End: 2029-12-01

December 1, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: December 1, 2029
Company: PROKIDNEY CORP. (PROK)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type

December 1, 2029

PROK overview →

Company: PROKIDNEY CORP. (PROK)
Indication: Chronic Kidney Diseases; Type 2 Diabetes Mellitus